Related Experiment Videos
Brain metastasis responding to gefitinib alone
Annette N Y Poon1, Simon S M Ho, Winnie Yeo
1Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Oncology
|November 13, 2004
Summary
Gefitinib monotherapy showed a dramatic clinical improvement in a patient with non-small cell lung cancer (NSCLC) brain metastases. This targeted therapy may offer a new treatment option for NSCLC patients with brain metastases.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) frequently metastasizes to the brain.
- Brain metastases in NSCLC often require combination therapy including corticosteroids and radiotherapy.
- Chemotherapy can be limited by efficacy and side effects in treating brain metastases.
Observation:
- A patient with stage IIIb NSCLC and brain metastases progressed during chemotherapy.
- Unusual circumstances led to gefitinib monotherapy without corticosteroids or radiotherapy.
- The patient experienced rapid clinical improvement within one week of gefitinib treatment.
Findings:
- Magnetic resonance imaging (MRI) 1 month post-treatment showed reduced size and number of brain metastases.
- The patient remained clinically stable for 9 months on gefitinib.
- Gefitinib demonstrated significant efficacy in managing brain metastases.
Implications:
- Gefitinib monotherapy may be a viable treatment option for NSCLC brain metastases.
- This case suggests a potential role for targeted therapy in overcoming brain barriers.
- Further research is warranted to explore gefitinib's efficacy and safety in treating brain metastases from NSCLC.